Observational Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Feb 21, 2024; 30(7): 685-704
Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.685
Figure 1
Figure 1 Experimental design. Clinically Significant Portal Hypertension Rule-in Liver Stiffness Measurement > 25 kPa. 1Baveno VI criteria; 2Baveno VII criteria. AD: Acute decompensation; NAD: Non-acute decompensation; LSM: Liver Stiffness Measurement; CSPH: Clinically Significant Portal Hypertension; MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease; cACLD: Compensated advanced chronic liver disease; BMI: Body mass index; Whr: Waist-to-hip ratio; SBP: Systolic; DBP: Diastolic blood pressure; CP: Child-Pugh; MELD: Model for End-Stage Liver Disease; APRI: Aspartate aminotransferase/platelet count ratio index; ALBI: Albumin-Bilirubin; FIB-4: Fibrosis-4; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International Normalized Ratio; PLT: Platelet; RDW: Red cell distribution width; FPG: Fasting plasma glucose; HOMA-IR: Homeostasis model assessment for insulin resistance; LDL: Low-density lipoprotein; HDL: High-density lipoprotein.